Answers are grounded in this paper and cite their sources.
PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and BRCA-mutated (BRCAm) cancer treatment. Clin Cancer Res; 24(17); 4062–5.
No takes yet. Share an insight, caveat, or question.
Konstantinopoulos et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: